Revaprazan is a novel acid pump antagonist (APA). It is a selective potassium-competitive acid blocker, to be specific, that reversibly inhibits gastric H(+)/K(+)-ATPase and shows effective acid suppression comparable to PPIs. References: Kim JH, Kim EH, Ock C, Hong H, Kim YJ, Kwon KA, Park DK, Hahm KB. Mitigating endoplasmic reticulum stress with revaprazan ameliorates stress-related mucosal disease. J Gastroenterol Hepatol. 2012 Jan;27(1):120-9. doi: 10.1111/j.1440-1746.2011.06838.x. PubMed PMID: 21722181.

纯度：≥98%

CAS：199463-33-7